Health Catalyst, Inc. (HCAT)
| Market Cap | 129.31M -51.6% |
| Revenue (ttm) | 302.48M -2.8% |
| Net Income | -265.26M |
| EPS | -3.74 |
| Shares Out | 73.89M |
| PE Ratio | n/a |
| Forward PE | 192.31 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,484,234 |
| Open | 1.690 |
| Previous Close | 1.720 |
| Day's Range | 1.670 - 1.795 |
| 52-Week Range | 0.955 - 4.125 |
| Beta | 1.66 |
| Analysts | Buy |
| Price Target | 1.75 (0.0%) |
| Earnings Date | Aug 6, 2026 |
About HCAT
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations in the United States. The company operates in two segments: Technology and Professional Services. It offers ignite data and analytics platform that provides clients a single comprehensive environment to integrate and organize data from their disparate software systems; and applications, a software analytics applications build for ignite platform to analyze clients face across clinical improvement, revenue and cost improvement, ambulatory operat... [Read more]
Financial Performance
In 2025, Health Catalyst's revenue was $311.14 million, an increase of 1.48% compared to the previous year's $306.58 million. Losses were -$177.97 million, 156.1% more than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for HCAT stock is "Buy." The 12-month stock price target is $1.75, which is no change of 0.00% from the latest price.
News
Health Catalyst to Participate in Upcoming Investor Conference
SALT LAKE CITY, June 16, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health sy...
Med-Metrix Enters Into Definitive Agreement to Acquire Vitalware to Enhance Coding Accuracy and Net Revenue Yield
PARSIPPANY, N.J., June 4, 2026 /PRNewswire/ -- Med-Metrix, LLC ("Med-Metrix"), backed by Harvest Partners and A&M Capital Partners, today announced it has entered into a definitive agreement to acquir...
Health Catalyst to divest Vitalware to Med-Metrix for $147M in cash
Health Catalyst (HCAT) announced it has signed a definitive agreement to divest Vitalware and the Vitalware business unit, its mid-revenue cycle business, to Med-Metrix for a total consideration of $1...
Health Catalyst to Divest Vitalware for $147 Million, Accelerating Strategic Transformation
Health Catalyst today announced it has signed a definitive agreement to divest Vitalware, its mid-revenue cycle business, to Med-Metrix for $147 million.
Health Catalyst Proxy statement: Proxy filing
Health Catalyst filed a proxy statement on June 3, 2026, providing details for shareholder voting and corporate governance matters.
Health Catalyst Proxy statement: Proxy filing
Health Catalyst filed a proxy statement on June 3, 2026, providing details for shareholder voting and corporate governance matters.
Health Catalyst Proxy statement: Proxy filing
Health Catalyst filed a proxy statement on May 19, 2026, providing details for shareholder voting and corporate governance matters.
Health Catalyst price target lowered to $1.75 from $2 at Stephens
Stephens lowered the firm’s price target on Health Catalyst (HCAT) to $1.75 from $2 and keeps an Equal Weight rating on the shares. The combination of better-than-expected Q1 and below-consensus…
Health Catalyst reports Q1 adjusted EPS 2c, consensus 1c
Reports Q1 revenue $70.76M, consensus $69.19M. “We delivered solid first quarter results, with revenue and adjusted EBITDA exceeding expectations,” said Ben Albert, Chief Executive Officer of Health C...
Health Catalyst sees Q2 revenue $68M-$70M, consensus $70.47M
Sees Q2 adjusted EBITDA $9M-$10M.
Health Catalyst sees FY26 revenue $260M-$265M, consensus $278.88M
Sees FY26 adjusted EBITDA $30M-$33M.
Health Catalyst Earnings Call Transcript: Q1 2026
Q1 2026 results exceeded expectations for revenue and adjusted EBITDA, driven by strong bookings and operational transformation. Project Nexus restructuring targets $30M in annualized savings, while the company shifts to a technology-led, AI-driven model amid ongoing migration-related revenue pressure.
Health Catalyst Earnings release: Q1 2026
Health Catalyst released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Health Catalyst Quarterly report: Q1 2026
Health Catalyst has published its Q1 2026 quarterly earnings report on May 11, 2026.
Health Catalyst Reports First Quarter 2026 Results
SALT LAKE CITY, May 11, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health sys...
Health Catalyst to Announce First Quarter 2026 Operating Results and Host Conference Call on Monday, May 11, 2026
SALT LAKE CITY, May 01, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health sys...
Health Catalyst Appoints Steve Nelson, President of Aetna, to Its Board of Directors
SALT LAKE CITY, April 30, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst”, Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health s...
Health Catalyst announces 9% global workforce reduction
In a regulatory filing, the company said, “As part of Project Nexus, a strategic initiative designed to fundamentally transform the company’s operating model, simplify its organizational structure, an...
Health Catalyst says Linda Llewelyn will cease to serve as Chief People Officer
In a regulatory filing, the company said, “On April 24, 2026, the Board of Directors of Health Catalyst (HCAT) determined that Linda Llewelyn will cease to serve as the Chief…
Wells Fargo downgrades Health Catalyst with ‘no easy fix’
Wells Fargo downgraded Health Catalyst (HCAT) to Equal Weight from Overweight with a price target of $1, down from $5. The company’s revenue and margin pressures appear likely to persist…
Health Catalyst downgraded to Equal Weight from Overweight at Wells Fargo
Wells Fargo downgraded Health Catalyst (HCAT) to Equal Weight from Overweight with a price target of $1, down from $5.
Health Catalyst price target lowered to $2 from $3.50 at Stephens
Stephens lowered the firm’s price target on Health Catalyst (HCAT) to $2 from $3.50 and keeps an Equal Weight rating on the shares. Q4 results were modestly ahead of expectations,…
Health Catalyst price target lowered to $3 from $4 at Cantor Fitzgerald
Cantor Fitzgerald lowered the firm’s price target on Health Catalyst (HCAT) to $3 from $4 and keeps a Neutral rating on the shares. There are elements of Health Catalyst’s story…
Health Catalyst price target lowered to $2 from $3.75 at Stifel
Stifel lowered the firm’s price target on Health Catalyst (HCAT) to $2 from $3.75 and keeps a Hold rating on the shares. Q4 results were modestly better than pre-release, but…
Health Catalyst price target lowered to $2 from $5 at Canaccord
Canaccord analyst Richard Close lowered the firm’s price target on Health Catalyst (HCAT) to $2 from $5 and keeps a Buy rating on the shares. The firm maintained its rating…